Search

Displaying results 9201 - 9210 of 10000 in total
  1. Drug

    R112

    go.drugbank.com/drugs/DB06252
    Experimental

    R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

  2. Drug

    MLN2704

    go.drugbank.com/drugs/DB06513
    Investigational

    A Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.

  3. Drug

    R-1487

    go.drugbank.com/drugs/DB06518
    Experimental

  4. Drug

    Lanimostim

    go.drugbank.com/drugs/DB06559
    Experimental

  5. Drug

    Vipadenant

    go.drugbank.com/drugs/DB06625
    Investigational

  6. Drug

    Zibotentan

    go.drugbank.com/drugs/DB06629
    Investigational

  7. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.

  8. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.

  9. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  10. Drug

    Cantuzumab ravtansine

    go.drugbank.com/drugs/DB05594
    Investigational